Australia's Firebrick Pharma jumps on manufacturing new product for export
** Shares of Firebrick Pharma FRE.AX rise as much as 15.6% to A$0.074, their highest level since September 8 ** Stock logs biggest intraday pct rise since June 10 ** Pharmaceutical co commences manufacturing of Nasodine Throat Spray for export in November 2025 ** Stock is up 19.4% YTD, including the session's moves (Reporting by Anjali Singh in Bengaluru) ((anjali.singh2@thomsonreuters.com;))
Recent news on Firebrick Pharma
See all newsAustralia's Firebrick Pharma jumps on plan to launch Nasodine products in US retail market
Brief: Firebrick Pharma Receives A$293,000 Research And Development Tax Incentive
Brief: Firebrick Pharma Says Nasodine Composition Patent Granted In New Zealand
Brief: Firebrick Pharma Says Nasodine Patent Accepted In Canada
Brief: Firebrick Pharma Secures A$1.5 Million Via Placement